Retroperitoneal fibrosis medical therapy

Retroperitoneal fibrosis Microchapters
Home
Patient Information
Overview
Pathophysiology
Causes
Differentiating Retroperitoneal fibrosis from other Diseases
Epidemiology and Demographics
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Retroperitoneal fibrosis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Retroperitoneal fibrosis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Retroperitoneal fibrosis medical therapy
CDC on Retroperitoneal fibrosis medical therapy
Retroperitoneal fibrosis medical therapy in the news
Blogs on Retroperitoneal fibrosis medical therapy
Directions to Hospitals Treating Retroperitoneal fibrosis
Risk calculators and risk factors for Retroperitoneal fibrosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

In the absence of severe urinary tract obstruction (which generally requires surgery with omental wrapping) treatment is generally with glucocorticoids initially, followed by DMARDs either as steroid-sparing agents or if refractory on steroids. The SERM tamoxifen has shown to improve the condition in various small trials, although the exact mechanism of its action remains unclear.

Contraindicated medications

History of retroperitoneal fibrosis is considered an absolute contraindication to the use of the following medications:

• Cabergoline